Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control. Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific. Protocol Amendment Number 03 - Site Specific - Germany (Version 2.0, Date 02-Oct-2006). Protocol Amendment Number 06 - Germany (Version 1.0, Date 12-Feb-2007). Protocol Amendment Number 07 - Site Specific (Version 1.0, Date 27-Sep-2007)
To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in A1C level achieved with each dose of saxagliptin plus metformin IR compared to saxagliptin plus...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Protocol version 1.0 dated 2004-10-05, and Amendment 01 country specific version 1.0 dated 2005-03-14
The primary objective of this study is to estimate the complete and overall hematologic response rates to BMS-354825 in accelerated phase CML subjects with primary or acquired resistance to imatinib m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of venous thromboembolism in acutely III medical subjects during and following hospitalization
To demonstrate that oral administration of apixaban 2.5 mg BID for 30 days reduces the rate of total venous thromboembolism (VTE) and VTE-related death compared to standard, subcutaneous administratio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues, While on Risperidone. Protocol version 1.0 dated 2005-03-31, and Pharmacogenetics Blood Sample Amendment 01, version 1.0 dated 2005-04-11
To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery. Revised Protocol 02: Incorporating Protocol Amendment 02 (v2.0, date 18-Apr-2007) and Protocol Amendment 04 (v2.0, date 05-May-2008). And Pharmacogenetics Blood Sample Amendment 01 (v2.0, date 31-Jan-2007) And PK Substudy Protocol Amendment 03 - Site Specific (v1.0, date 29-Apr-2008). And Revised Prococol 03 Incorporating Protocol Amendment 05 (v1.0 dated 31-Oct-2008) and Admin Letter 02 (v2.0 dated 12-Jun-2008)
To compare the effect of oral apixaban 2.5 mg BID versus subcutaneous (SC) enoxaparin 40 mg QD on the composite endpoint of adjudicated asymptomatic and symptomatic DVT, non-fatal PE and all cause dea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control with Diet and Exercise and a Stable Dose of Metformin XR ≥ 1500 mg/day Revised Protocol 01 incorporating Protocol Amendment 01 (v1.0, dated 24-Jul-2008)
To compare after 4 weeks of oral administration of double-blind treatment, the change from baseline in 24-hour mean weighted glucose achieved with saxagliptin 5 mg versus placebo as add on treatment ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólico
The primary objective is to compare the change from baseline in insulin resistance (IR, as measured by the Matsuda Index) in patients with hypertension and metabolic syndrome after 16 Weeks of monothe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study evaluating Asunaprevir and Daclatasvir in combination with Pegasys and Copegus, in Genotype 1 and 4 Subjects with Chronic Hepatitis C who do not adequately respond to Peginterferon Alfa 2a or 2b plus Ribavirin. Studio per valutare Asunaprevir e Daclatasvir in combinazione con Pegasys e Copegus (P/R) (QUAD) nei soggetti affetti da epatite cronica C che non rispondono adeguatamente a Peginterferone Alfa 2a o Alfa 2b e Ribavirina
To assess efficacy, as determined by the proportion of subjects with SVR12, defined as HCV RNA < LOQ at post-treatment Week 12. Valutare l’efficacia, determinata dalla proporzione di soggetti c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT) Amendment 1 and Revised protocol Number:01 (Incorporates Amendment 2 & Administrative Letter 1)
• Evaluate the effects of belatacept, relative to CsA, on the composite of subject and graft survival at 12 months • Evaluate the effects of belatacept, relative to CsA, on the composite of measured G...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant